Hovione
↗Loures, Lisbon, Portugal
Hovione is an independent, family-owned Contract Development and Manufacturing Organization (CDMO) founded in 1959 and headquartered in Loures, Portugal. With over 65 years of industry expertise, the company specializes in developing and manufacturing active pharmaceutical ingredients (APIs) and drug products for oral, topical, inhalation, and injectable formulations. Hovione operates a fully integrated global platform serving 19 of the world's 20 largest pharmaceutical companies, providing end-to-end solutions from discovery through manufacturing at scale. The company combines traditional chemistry expertise with cutting-edge process technologies including spray drying, controlled crystallization, microfluidization, and continuous tabletting.
CLASSIFICATION
Company Type:CDMO
Therapeutic Areas:
Industry:Pharmaceuticals / Biotech
Sub-Industry:Contract Development and Manufacturing Organization (CDMO) - Active Pharmaceutical Ingredients (APIs)
SIZE & FINANCIALS
Employees:1001-5000
Revenue:$283M-$410M
Founded:1959
Ownership:private
Status:operating
FUNDING
Stage:Privately held family business
PIPELINE
Stage:Phase 2/3
Lead Drug Stage:Phase 2 completed (HY02/Meizuvo) - Phase 3 planned
Modalities:Small molecule APIs, Inhalation formulations, Topical formulations, Injectable formulations, Dry powder inhalers, Amorphous Solid Dispersions (ASDs)
Active Trials:1
Trial Phases:Phase 2: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Hovione New Jersey LLC (USA), Hovione Macau (China), Hovione Taizhou (China), Hovione Cork (Ireland), Hovione Portugal (Portugal)
Key Partnerships:Zerion Pharma - Dispersome® technology joint venture (October 2024), Ligand Pharmaceuticals - Captisol® co-promotion agreement, Gilead Sciences - Veklury (remdesivir) manufacturing partnership, Firstgene Life Sciences/Xlife Sciences - Hepatocellular carcinoma drug delivery collaboration, Microinnova Engineering - Flow chemistry and continuous process intensification, Dragonfly Technologies - Micellar chemistry partnership, GEA - Continuous tableting technology partnership, H&T Presspart - Dry powder inhaler device technology, IDC - Nasal powder delivery devices
COMPETITION
Position:Challenger / Significant player (ranked #39 among 337 active CDMO competitors)
Competitors:Lonza (largest CDMO globally), Concord Biotech, Almac Group, BDR Pharmaceuticals, Cambrex Corporation, CARBOGEN AMCIS, CordenPharma, Flamma Group +2 more
LEADERSHIP
Key Executives:
Jean-Luc Herbeaux - CEO
Marco Gil - Senior Vice President, Sales & Marketing
Liam Keary - Vice President, Global Head of Quality
Tiago Ferreira de Matos - Group General Counsel
Ilda Ventura - Senior Vice President, Human Resources
Scientific Founders:Ivan Villax (Founder), Diane Villax (Founder), Nicholas de Horthy (Hungarian refugee co-founder), Andrew Onody (Hungarian refugee co-founder)
LINKS
Website:hovione.com
LinkedIn:LinkedIn Profile
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Hovione and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Hovione. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.